Silicone Breast Implant Research and Information Act
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers would be required to update package inserts and informed consent documents to reflect accurate information about the rupture rate of the devices under legislation introduced June 10 by Sen. Barbara Boxer (D-Calif.). Firms also would be required to provide informed consent documents at "the initial or earliest possible consultation regarding breast prosthesis, inform women on how to obtain a Medwatch (adverse event reporting) form, and provide potential study participants with the inclusion criteria for the trial and the toll-free consumer information number." In general, the bill authorizes the National Institutes of Health to expand research on the health implications of silicone breast implants, including undertaking a large neurological/immune dysfunction study of women implanted with the devices for at least eight years
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.